Results 201 to 210 of about 81,608 (302)

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma. [PDF]

Int J Mol Sci, 2023
Deiana C, Fabbri F, Tavolari S, Palloni A, Brandi G.   +4 more
europepmc   +1 more source

Rare comorbidity of colon cancer, hepatic malignant mesothelioma, and abdominal Ewing's sarcoma: a case report. [PDF]

Front Oncol
Li Y, Teng L, Wang S, Wu X, Huang T.
europepmc   +1 more source

Kindlin‐2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration [PDF]

, 2010
Zhengwen An, Katalin Dobra, John G. Lock, Staffan Strömblad, Anders Hjerpe, Hongquan Zhang   +5 more
openalex   +1 more source

Volatile organic compounds as a diagnostic tool for malignant pleural mesothelioma [PDF]

, 2013
Lamote, Kevin, Nackaerts, Kristiaan, Van Cleemput, Joris, Van Meerbeeck, Jan   +3 more
core   +3 more sources

Modeling Malignant Mesothelioma in Genetically Engineered Mice. [PDF]

Curr Protoc
Kadariya Y, Sementino E, Hua X, Kappes DJ, Testa JR.   +4 more
europepmc   +1 more source

Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma. [PDF]

Int J Mol Sci, 2023
Zupanc C, Franko A, Štrbac D, Kovač V, Dolžan V, Goričar K.   +5 more
europepmc   +1 more source

Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB. [PDF]

J Transl Med
Belgiovine C, Digifico E, Erreni M, Putignano AR, Mannarino L, Valentino S, Grizzi F, Pasqualini F, Recordati C, Bertola L, Zucali P, Pistillo D, Paleari V, Mantovani A, D'Incalci M, Marchesi F, Allavena P.   +16 more
europepmc   +1 more source

Comprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma. [PDF]

Medicine (Baltimore), 2023
Weng J, Chen J.
europepmc   +1 more source

Abstracts

Cancer Science, Volume 117, Issue S1, Page 1-2148, January 2026.
wiley   +1 more source

First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. [PDF]

ESMO Open
Minchom A, Lindén O, Knapen DG, Hassan R, Lin FI, Jalkanen K, Subbiah V, Tafuri A, Ferreira D, Jardine V, Cleton A, Pinkert J, Bladt F, Hennekes H, Smit EF.   +14 more
europepmc   +1 more source